This survival impact of low HLA-A was considered specific to TFDC immunotherapy, as analysis of the CGGA GBM dataset revealed no association of HLA-A, HLA-B, and HLA-C with survival (Fig. 2h–j). The gene discussed is HLA-A; the disease is glioblastoma.